Phathom Pharmaceuticals

PHAT39

$18.72arrow_drop_down2.65%-$0.51

PHAT39

$18.72

arrow_drop_down2.65%-$0.51

Performance History

Key Stats
Open	$19.63
Prev. Close	$19.23
EPS	-5.18
Dividend	Non-Dividend
Next Earnings Date	-
Dividend Yield %	-

PE Ratio	-

	LOW	HIGH
Day Range	18.54	19.71
52 Week Range	6.06	19.71

Ratios

Revenue	-



EBITDA Margin %	-

EPS	-5.18

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

•

Analyst Ratings

•

About Phathom Pharmaceuticals (PHAT)

Phathom Pharmaceuticals Inc (PHAT) is a leading biopharmaceutical company focused on the development and commercialization of novel treatments for gastrointestinal diseases. With a strong emphasis on research and development, the company is dedicated to improving the lives of patients suffering from conditions such as gastroesophageal reflux disease (GERD) and other acid-related disorders. PHAT is committed to advancing innovative therapies that address unmet medical needs and provide patients with improved outcomes.

The stock price history of Phathom Pharmaceuticals Inc (PHAT) reflects the company's significant growth and potential. Over the past few years, the stock has seen a steady increase in value, driven by positive clinical trial results and promising drug development programs. Investors have shown confidence in PHAT's ability to deliver groundbreaking treatments and the stock has responded accordingly. With a strong pipeline of potential therapies, Phathom Pharmaceuticals Inc is well-positioned for future success.

Websitecall_made

Sector: Healthcare
Industry: Biotechnology
CEO: Ms. Terrie J. Curran
Headquarters: Florham Park
Employees: 112
Exchange: NASDAQ

add Phathom Pharmaceuticals to watchlist

Keep an eye on Phathom Pharmaceuticals

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

help

What is the market capitalization of Phathom Pharmaceuticals (PHAT)?

Phathom Pharmaceuticals (PHAT) has a market capitalization of $1.31B. The average daily trading volume is 1.35M, indicating the stock's liquidity and investor engagement.

help

What is Phathom Pharmaceuticals 's (PHAT) price per share?

The current price per share for Phathom Pharmaceuticals (PHAT) is $18.72. The stock has seen a price change of -$0.51 recently, indicating a -2.65% change. This reflects the stock's recent market performance and investor sentiment.

help

What is the 52-week high and low for Phathom Pharmaceuticals (PHAT)?

For Phathom Pharmaceuticals (PHAT), the 52-week high is $19.71, which is 5.29% from the current price. The 52-week low is $6.06, the current price is 208.66% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.

help

Is Phathom Pharmaceuticals (PHAT) a growth stock?

Phathom Pharmaceuticals (PHAT) has shown an average price growth of 0.41% over the past three years. It has received a score of 16 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Phathom Pharmaceuticals as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.

help

What is Phathom Pharmaceuticals (PHAT) stock price performance year to date (YTD)?

As of the latest data, Phathom Pharmaceuticals (PHAT) has a year-to-date price change of 104.14%. Over the past month, the stock has experienced a price change of 45.23%. Over the last three months, the change has been 57.71%. Over the past six months, the figure is 126.09%.

help

Is Phathom Pharmaceuticals (PHAT) a profitable company?

Phathom Pharmaceuticals (PHAT) has a net income of -$201.59M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of 75.51% indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of -1.06K% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at , although specific revenue growth data is currently not available. The gross profit is $515K. Operating income is noted at -$167.31M. Furthermore, the EBITDA is -$252.07M.